drugset
Drugs / pp65 RNA LP (DP1)
last change Mar 2025 re-read 3 minutes ago

pp65 RNA LP (DP1)

Vaccine

Developed for
malignant glioma · osteosarcoma
Investigated by
Alex's Lemonade Stand Foundation · National Cancer Institute (NCI) · National Pediatric Cancer Foundation · The Osteosarcoma Institute · The V Foundation for Cancer Research · University of Florida

Trials 1

today NCT05660408 · Ph 1/2
2025202620272028202920302031203220332034
PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 1/2 NCT05660408 Mar 2025 → Oct 2033 expected malignant glioma, osteosarcoma University of Florida Active not recruiting No outcome recorded

Evidence & citations 2 cited values

Every value below carries the sentence it was read from. 1 source stands behind the page.

FieldValueCited text
Known as pp65 RNA LP (DP1) ClinicalTrials.gov intervention name — accepted as the source's own label NCT05660408 ↗
Modality Vaccine “This is an off the shelf RNA-LP vaccine used to prime for the immune response” NCT05660408 ↗